文献速递免疫规划传染病防控与疫情报告

加拿大国家疫苗安全网络中老年人mRNA COVID-19疫苗安全性研究

mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network.
PubMed 文献 · Vaccine · 2024-05-06

本研究利用加拿大国家疫苗安全网络主动监测数据,分析≥65岁老年人接种mRNA COVID-19疫苗的短期至中期安全性。共173,038、104,452和13,970名老年人分别完成第1、2、3剂调查,2,955名未接种者完成对照调查。结果显示,同源mRNA-1273第2剂后及异源第2剂后健康事件发生率高于未接种者,但所有产品各剂次严重健康事件率≤0.3%,且与未接种对照相比未升高。

要点

  • 同源mRNA-1273第2剂后健康事件调整OR为2.91(95%CI 2.24-3.79),高于未接种对照。
  • 异源第2剂(BNT162b2后mRNA-1273)健康事件调整OR为1.50(95%CI 1.12-2.02),高于未接种对照。
  • 所有疫苗产品各剂次严重健康事件率≤0.3%,与未接种对照相比未升高。

核心结论

  • 研究结果进一步强化了当前证据,即mRNA COVID-19疫苗是安全的,可用于告知老年人接种后预期的不良事件。

研究设计与样本

  • 利用加拿大国家疫苗安全网络主动安全监测数据,纳入来自七个省和地区的接种与未接种≥65岁老年人。
  • 安全性评估在COVID-19疫苗接种后7天(第1、2、3剂)及第1剂后7个月进行。
  • 采用多变量逻辑回归分析BNT162b2/mRNA-1273 COVID-19疫苗与两种短期健康事件的关联。

主要发现

  • 2020年12月至2022年2月,分别有173,038、104,452和13,970名老年人完成第1、2、3剂调查,2,955名未接种老年人完成对照调查。
  • 同源mRNA-1273第2剂后健康事件调整OR为2.91(95%CI 2.24-3.79),异源第2剂(BNT162b2后mRNA-1273)调整OR为1.50(95%CI 1.12-2.02),均高于未接种对照。
  • BNT162b2任何剂次后事件率与未接种参与者无差异。
  • 所有疫苗产品和剂次的严重健康事件率非常低(≤0.3%),与未接种对照相比未升高,且与接种后7天内急诊就诊或住院无关。
  • 报告的症状为自限性,很少需要医学评估。

临床怎么用

  • 研究结果可用于告知老年人COVID-19疫苗接种后预期的不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study examined short-to-medium term safety of COVID-19 vaccines among adults aged ≥65 years using the Canadian National Vaccine Safety Network active safety surveillance data. Both vaccinated and unvaccinated older adult participants recruited from seven provinces and territories were included in the analysis. Safety was assessed at 7 days after COVID-19 vaccination (dose 1, 2 and 3), and 7 months after dose 1. Multivariable logistic regression was used to examine the association between BNT162b2/mRNA-1273 COVID-19 vaccines and two short-term health events: 1) health event preventing daily activities and/or required medical consultation, 2) serious health events resulting in an emergency department visit and/or hospitalization within 7 days following each dose. We also assessed the rates of serious health events for the period between dose 1 and 2, and 7-months following dose 1. Between December 2020 and February 2022, a total of 173,038, 104,452, and 13,970 older adults completed dose 1, dose 2, and dose 3 surveys, respectively. The control survey was completed by 2,955 unvaccinated older adults. Health events occurred more frequently among recipients after dose 2 homologous mRNA-1273 (adjusted odds ratio [95 % confidence interval]: 2.91 [2.24-3.79]) and dose two heterologous (BNT162b2 followed by mRNA-1273): 1.50 [1.12-2.02] compared to unvaccinated counterparts. There was no difference in event rates after any dose of BNT162b2 and unvaccinated participants. The rates of serious health events following COVID-19 vaccination were very low (≤0.3 %) across all vaccine products and doses, and were not higher compared to unvaccinated controls, and were not associated with an emergency department visit or hospitalization within 7 days following vaccination. Reported symptoms were self-limited and rarely required medical assessment. Our findings further strengthen the current evidence that mRNA COVID-19 vaccines are safe and can be used to inform older adults about expected adverse events following COVID-19 vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Soe P, Wong H, Naus M, et al. mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network. Vaccine. 2024. PMID: 38714447. doi:10.1016/j.vaccine.2024.04.096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。